Roche reports positive Phase II results for experimental eye drug

New Drug Approvals

Lampalizumab

Roche reports positive Phase II results for experimental eye drug
Lampalizumab, an experimental eye drug from Roche, has helped slow down the progression of an advanced form of age-related macular degeneration (AMD) in a Phase II study, the company announced this week.

READ ALL AT

 http://www.pharmaceutical-technology.com/news/newsroche-reports-positive-phase-ii-results-experimental-eye-drug?WT.mc_id=DN_News

SEE ALSO

Lampalizumab effective in Phase II clinical trial for macular degeneration

Roche’s new drug for age-related macular degeneration, lampalizumab, showed effective in slowing the progression of AMD in patients with advanced disease, shrinking the area of geographic atrophy by 20%. Read More >>

 

Lampalizumab (INN) is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration. It binds to CFD.[1][2]

This drug was developed by Genentech/Roche.

References

  1. ^World Health Organization (2012). “International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107” (PDF). WHO Drug…

View original post 21 more words

Advertisements

Roche reports positive Phase II results for experimental eye drug

New Drug Approvals

Lampalizumab

Roche reports positive Phase II results for experimental eye drug
Lampalizumab, an experimental eye drug from Roche, has helped slow down the progression of an advanced form of age-related macular degeneration (AMD) in a Phase II study, the company announced this week.

READ ALL AT

 http://www.pharmaceutical-technology.com/news/newsroche-reports-positive-phase-ii-results-experimental-eye-drug?WT.mc_id=DN_News

SEE ALSO

Lampalizumab effective in Phase II clinical trial for macular degeneration

Roche’s new drug for age-related macular degeneration, lampalizumab, showed effective in slowing the progression of AMD in patients with advanced disease, shrinking the area of geographic atrophy by 20%. Read More >>

 

Lampalizumab (INN) is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration. It binds to CFD.[1][2]

This drug was developed by Genentech/Roche.

References

  1. ^World Health Organization (2012). “International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107” (PDF). WHO Drug…

View original post 21 more words

NATURE’S VIAGRA-Health benefits of pomegranate by – By Dr. Janardhana V Hebbar, Ayurveda Expert

New Drug Approvals

Image

Countless studies have shown the seemingly countless benefits of fruits for a person’s health.

The U.S. Government recommends that people get some servings of fruits every day. Of all the fruits ready in the shop today,

one fruit is at its height of popularity because of its legendary Greek mythology connection and its exoticism-the pomegranate fruit.

READ COMPLETE ARTICLE AT

http://www.askveda.in/blog/health-benefits-of-pomegranate/

 

 

View original post

GLENMARK-A new way for a new world

New Drug Approvals

GlenmarkLogo.jpg

http://www.glenmarkpharma.com/GLN_NWS/homepage.aspx?res=P_GLN

http://www.glenmark-generics.com/

Type Public
Traded as BSE532296NSEGLENMARK)
Industry PharmaceuticalsDrugs &Healthcare
Founded 1977
Founder(s) Gracias Saldanha
Headquarters MumbaiMaharashtra[1]India
Key people Glenn Saldanha, MD & CEO [2]
Products Medicines and Vaccines
Revenue INR1031.10 crore(US$160 million) (2009–2010)[3]
Employees 7,000 [4]
Subsidiaries Glenmark Generics Ltd[5]
Website www.glenmarkpharma.com

Glenmark Pharmaceuticals is a pharmaceutical company headquartered in MumbaiIndia[6] It manufactures and markets generic formulation products and active pharmaceutical ingredients (API), both in the domestic and international markets. In the formulation business, its business spans segments such as DermatologyInternal MedicinePaediatricsGynaecologyENT andDiabetes.

It has four manufacturing facilities for formulations and additional three facilities for APIs. These manufacturing facilities are located in the states of MaharashtraGoaHimachal Pradesh and Gujarat in India.

It…

View original post 1,595 more words

Bupropion review

New Drug Approvals

File:Bupropion skeletal.svg

Bupropion

Bupropion (/bjuːˈprpi.ɒn/ bew-proh-pee-on;[2] ) is a drug that is primarily used as an atypical antidepressant and smoking cessation aid. Marketed as WellbutrinBudeprionPrexatonElontrilAplenzin, or other trade names, it is one of the most frequently prescribed antidepressants in the United States. Marketed in lower-dose formulations as ZybanVoxra, or other names, it is also widely used to reduce nicotine cravings by people who are trying to quit smoking. It is taken in the form of pills, and in the United States is available only by prescription.

Bupropion lowers seizure threshold, and its potential to cause seizures has been widely publicized. Bupropion is an effective antidepressant on its own, but it is also popular as an add-on medication in cases of incomplete…

View original post 2,551 more words

Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon

New Drug Approvals

"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw. (BCCL)“We have focused on creating key growth drivers and have structured the company along those growth drivers,” says Kiran Mazumdar Shaw. (BCCL)…………. owner BIOCON

MY, DR AMC  COMMENTS- BIOCON GREAT PERFORMANCE, U ARE EVERYWHERE

 

Kiran Mazumdar Shaw: We have focused on creating key growth drivers and have structured the company along those growth drivers. These growth drivers are beginning to deliver very strongly for us.

The first is our small molecule business vertical, which is about our historic statins and immunosuppressant’s API business. This particular vertical going forward is envisioned to go up the value chain along an ANDA path and we believe that will improve the quality of earnings in this particular vertical, which for a long time was under pressure because of commoditisation of statins.http://economictimes.indiatimes.com/opinion/interviews/small-molecule-api-biz-to-be-growth-drivers-for-company-kiran-mazumdar-shaw-biocon/articleshow/21975113.cms

View original post

Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon

New Drug Approvals

"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw. (BCCL)“We have focused on creating key growth drivers and have structured the company along those growth drivers,” says Kiran Mazumdar Shaw. (BCCL)…………. owner BIOCON

MY, DR AMC  COMMENTS- BIOCON GREAT PERFORMANCE, U ARE EVERYWHERE

 

Kiran Mazumdar Shaw: We have focused on creating key growth drivers and have structured the company along those growth drivers. These growth drivers are beginning to deliver very strongly for us.

The first is our small molecule business vertical, which is about our historic statins and immunosuppressant’s API business. This particular vertical going forward is envisioned to go up the value chain along an ANDA path and we believe that will improve the quality of earnings in this particular vertical, which for a long time was under pressure because of commoditisation of statins.http://economictimes.indiatimes.com/opinion/interviews/small-molecule-api-biz-to-be-growth-drivers-for-company-kiran-mazumdar-shaw-biocon/articleshow/21975113.cms

View original post